Breast cancer remains the most lethal type of cancer for women. A significant proportion of breast cancer cases are characterised by overexpression of the human epidermal growth factor receptor 2 protein (HER2). These cancers are commonly treated by Herceptin (Trastuzumab), but resistance to drug treatment frequently develops in tumour cells. Dual-specificity phosphatases (DUSPs) are thought to play a role in the mechanism of resistance, since some of them were reported to be overexpressed in tumours resistant to Herceptin.
Background
Breast cancer is one of the most common and the most lethal type of cancer affecting women. Approximately one in eight women in the Western world develops breast cancer throughout her life [1] . HER2-positive cases represent about 25%, characterised by high levels of HER2 activity arising from mutations, overexpression of the HER2 protein or amplification of the HER2 gene [2, 3] .
HER2 (Neu or ErbB2) belongs to the protein tyrosine kinase (PTK) epidermal growth factor receptor family that consists of three other proteins: HER1, HER3 and HER4 [3] . All four HER receptors function as homo-or hetero-dimers that are activated by a variety of ligands, such as the epidermal growth factor (EGF), transforming growth factor a (TGFα), heparin-binding EGF-like growth factor and neuregulins (NGFs) [4, 5] . HER2 incorporates into heterodimers with the other HERs resulting in its activation. No ligand of HER2 has been discovered yet [6] . HER2 can also be activated by ligand-independent homodimerization that follows its overexpression in tumour cells [7] . Active HER2 auto-phosphorylates and binds to various molecules to activate signalling pathways, for example the Mitogen-Activated Protein Kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways, which collectively promote cell growth, proliferation and survival [8] .
Because of their critical roles in driving cancer, PTKs are major targets for therapy that is often administered in the form of small molecule inhibitors or neutralizing antibodies [9, 10]. HER2-positive breast cancer is commonly treated by Herceptin (Trastuzumab), a humanized monoclonal antibody that associates with the extracellular domain IV of the protein. Dimerization of HER2 is decreased by Herceptin, thereby inhibiting PI3K and MAPK pathways, promoting antibodymediated cellular cytotoxicity, and promoting HER2 ubiquitinylation and internalisation [8] . One third of HER2-positive breast cancer cases are responsive to Herceptin, but two thirds of these relapse within one year due to resistance to the drug that develops in the tumour cells [11, 12] [13] . Potential mechanisms for resistance to Herceptin include overexpression of other tyrosine kinases that replace HER2, structural alterations of HER2 that remove or mask the Herceptin binding-site on HER2, or alterations in downstream signalling pathways that reduce their dependence on HER2 [8-10]. Many efforts to overcome this resistance have been investigated including combination of Herceptin with other drugs that target HER2 (e.g. Lapatinib) or key downstream proteins (e.g. inhibitors of Raf, MEK and PI3K) [9, 14] .
In tumour cells, HER2 signalling is regulated by several MAPKs, most importantly ERK1, ERK2, p38, and JNK. These kinases are activated by phosphorylation of specific threonine and tyrosine residues by upstream kinases, and inactivated by dephosphorylation of either or both residues. Dephosphorylation is carried out by the dual-specificity phosphatases (DUSPs) which belong to the tyrosine phosphatase superfamily [15] . The DUSP family is comprised of ten MAPK phosphatases (MKPs) and of additional atypical DUSPs, which actively down-regulate MAPK activity [16, 17] In order to study Herceptin resistance in breast cancer we turned to two HER2positive human breast cancer cell lines: BT-474, which is estrogen receptor (ER) and progesterone receptor (PR) positive, and SK-BR-3, which is ER and PR negative [21, 22] . These differences determine unique clinical outcomes, specific responses to therapeutic strategies and specific progression of metastasis [23] . Reports indicate that exposing these cells to Herceptin leads to development of resistance to the drug after periods that range from 3 to 12 months [24-26] [27, 28] [20, 29] . The molecular mechanisms that lead to resistance in these cell lines, including the possible involvement of DUSPs in this process, are unknown.
Computational modelling is a well-recognised approach to study regulation of cell signalling processes and to predict their effects [30, 31] [32] . Creating kinetic models of signalling pathways is often challenging because the detailed dynamics and interactions of these pathways are usually not known, and complex experimentation is required to provide the missing data. An efficient alternative is to use Boolean models [33] , which reproduce the dynamics of the system in a qualitative manner by discretising levels of nodes into two possible states: 0 or 1. Interactions are similarly discretised into activation or inhibition [33] . We have previously constructed a series of Boolean models for short-term exposure of cells to Herceptin, which correctly accounted for the described regulatory mechanisms involving DUSPs [34] . The present study uses Boolean models combined with experimental data to identify DUSPs that may be targeted in breast cancer cells for reversing Herceptin resistance.
Methods

Cell lines
The human breast cancer cell lines BT-474 and SK-BR-3 were purchased from the American Type Culture Collection (Manassas, USA). BT-474 cells were cultured in DMEM medium containing 50 U/ml penicillin, 50 mg/ml streptomycin and 10% heat- together with target-specific primers (as described in [34] ). Amplification was performed on an AB StepOnePlus instrument (Applied Biosystems, Foster City, USA). The amplification conditions consisted of an initial activation step of 95°C (20 seconds), followed by 40 x (95°C, 3 seconds; 60°C, 30 seconds) and ending with 1 x (95°C, 15 seconds; 60°C, 60 seconds; 95°C, 15 seconds). CT method [35] . Experiments were performed in triplicate using two biological repeats. The Primer3 software was used to design DUSP-specific forward and reverse primers [36, 37], and their efficiency was assessed by standard curves.
Student's t-test was used to determine significance by the GraphPad Prism software (GraphPad Software, La Jolla, USA).
Construction of Boolean models
Boolean models were manually constructed and run as described previously [34] .
Cell survival was represented by adding a specific Survival node in the model. We added an activation link between ERK and Survival, since in healthy cells it is observed that ERK, JNK and p38 favour proliferation. In addition, we added an interaction that represents combined interaction of JNK and p38 inhibiting Survival. This is justified because the high levels of activity of JNK and p38 favour apoptosis and inhibition of cellular growth [38] [39] [40] [41] . When the Survival node is ON, the outcome should be interpreted as a set of cellular processes favouring proliferation; when the Survival node is OFF, the outcome should be interpreted as a set of cellular processes favouring cell death.
When both JNK and p38 are inhibited by DUSPs, cell death is prevented in tumour cells. We used information about DUSPs and their specific substrates published in the literature to connect them with their known kinases in our models [18, 42] . In order to simulate an overexpressed DUSP we introduced an unknown activator "A", which was kept ON during the whole time course. To simulate the inhibition of a targeted DUSP we introduced a node "I", which had an inhibitory action on its target and was kept ON permanently.
Results
Induction of Herceptin resistance by long-term treatment with the drug
In order to determine if long-term treatment with Herceptin induces resistance to the drug in the BT-474 and SK-BR-3 cell lines, cells from each line were cultured continuously for six months in the absence and presence, respectively, of 50 µM
Herceptin. Massive cell death was not observed during this prolonged period in cells treated with Herceptin. Then, aliquots of both treated and non-treated cells were exposed to 50 µM Herceptin for 72 hours, and their proliferation during this period was quantified. In agreement with previous reports [20, 24-28, 30], Herceptin inhibited proliferation of BT-474 and SK-BR-3 cells that had not been exposed to long-term Herceptin treatment. In contrast, proliferation of cells that had been exposed for 6 months to Herceptin was not affected by this additional 72-hour treatment with Herceptin ( Figure 1 ), confirming that they are resistant to the effects of the drug. 
Modelling selective inhibition of DUSPs in BT-474 cells
Boolean models were constructed to represent and simulate resistance to Herceptin 
Modelling selective inhibition of DUSPs in SK-BR-3 cells
We simulated overexpression of DUSPs for which regulatory mechanisms were known by applying an activator "A" and tested if inhibition of these DUSPs could reverse survival. We modelled the role of overexpressed DUSPs 4 and 6 in resistance separately in SK-BR-3 cells ( Figure 6, A-H Simulating the effects of overexpression and inhibition of DUSP8 indicated that, as was observed in BT-474 cells, Survival remains "ON" when this DUSP is overexpressed, but changes to "OFF" when this DUSP is inhibited (Figure 7, A, B) .
Similar effects were noted also for overexpression and inhibition of DUSP16 ( Figure   7 , C, D). DUSP8 and DUSP16 inhibit JNK and p38 [42], but the specific kinase involvement in their induction is not known. We further confirmed that irrespective of the activation of other DUSPs, such as DUSPs 4 and 6, Survival is switched OFF if DUSP8 is inhibited (Figure 7, C, D) . 
Discussion
In a previous study, we built several Boolean models to study the initial response of HER2-positive breast cancer cells to Herceptin and the contribution of DUSPs in pathways that signal cell survival [34] . We were able to explain the observed dynamics in the expression of several DUSPs playing a role in regulation of MAPK 
